MedTrace Logo

Etoposide in the First-line Treatment of Adult EBV-HLH

NCT03742115 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2018-11-15

No results posted yet for this study

Summary

his study aimed to investigate the efficacy of etoposide as the first line therapy for adult Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis.

Conditions

  • Hemophagocytic Lymphohistiocytosis

Interventions

DRUG

Etoposide

150 mg/m2 twice weekly for 2 weeks and then weekly

DRUG

Dexamethasone

initially 10 mg/m2 for 2 weeks followed by 5 mg/m2 for 2 weeks, 2.5 mg/m2 for 2 weeks, 1.25 mg/m2 for one week, and one week of tapering

DRUG

Etoposide

150 mg/m2 weekly

DRUG

IVIG

0.5 g/kg, once every 4 weeks

Sponsors & Collaborators

  • Beijing Friendship Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-12-01
Primary Completion
2019-12-01
Completion
2020-12-01

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03742115 on ClinicalTrials.gov